Churg-Strauss syndrome in patients treated with omalizumab

Chest

Volumn 136, Issue 2, 2009, Pages 507-518

  Wechsler, Michael E ^a   Wong, Dennis A ^b   Miller, Mary K ^b   Lawrence Miyasaki, Lisa ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUTICASONE; IMMUNOGLOBULIN E; MONTELUKAST; OMALIZUMAB; PREDNISONE; SALMETEROL; STEROID; ZAFIRLUKAST;

ARTICLE; ASTHMA; BELL PALSY; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EXPOSURE; DRUG MEGADOSE; DRUG USE; DRUG WITHDRAWAL; EOSINOPHILIA; HUMAN; HYPEREOSINOPHILIA; HYPERSENSITIVITY REACTION; HYPERTENSION; INCIDENCE; MONONEUROPATHY MULTIPLEX; PANCYTOPENIA; PHLEBITIS; POLYMYOSITIS; PREVALENCE; PRIORITY JOURNAL; SINUSITIS; STEROID THERAPY; SYMPTOMATOLOGY; TEMPORAL ARTERITIS; TREATMENT OUTCOME; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 68849090036     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-2990     Document Type: Article

References (48)

1. Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006; 117:1292-1302
2. Churg A, Brallas M, Cronin SR, et al. Formes frustes of Churg-Strauss syndrome. Chest 1995; 108:320-323
3. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279:455-457
4. Wechsler ME, Pauwels R, Drazen JM. Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal? Drug Saf 1999; 21:241-251
5. Srinivasan R, Deane PM. Development of Churg-Strauss syndrome after initiation of omalizumab [abstract]. Paper presented at: Annual meeting of the American College of Allergy, Asthma and Immunology, Philadelphia, PA, 2006; 27
6. Winchester DE, Jacob A, Murphy T. Omalizumab for asthma. N Engl J Med 2006; 355:1281-1282
7. Bargagli E, Madioni C, Olivieri C, et al. Churg-Strauss vasculitis in a patient treated with omalizumab. J Asthma 2008; 45:115-116
8. Bargagli E, Rottoli P. Omalizumab treatment associated with Churg-Strauss vasculitis. Int Arch Allergy Immunol 2008; 145:268
9. Puéchal X, Rivereau P, Vinchon F. Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med 2008; 19:364-366
10. Ruppert AM, Averous G, Stanciu D, et al. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol 2008; 121:253-254
11. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151:2623-2632
12. Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med 2001; 164:6-11
13. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-190
14. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108:E36
15. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-261
16. Lemanske RF, Nayak A, McAlary M, et al. Omalizumab improves asthma-related quality of life in children with allergic asthma [abstract]. Pediatrics 2002; 110:e55
17. Holgate ST, Chuchalin AG, et al. Omalizumab 011 International Study Group: efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632-638
18. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:302-308
19. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309-316
20. Humbert M, Berger W, Rapatz G, et al. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma. Allergy 2008; 63:592-596
21. Niven R, Chung KF, Panahloo Z, et al. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 2008; 102:1371-1378
22. Harrold LR, Andrade SE, Go AS, et al. Incidence of Churg-Strauss syndrome in asthma drug users: a population-based perspective. J Rheumatol 2005; 32:1076-1080
23. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33:1094-1100
24. Lilly CM, Churg A, Lazarovich M, et al. Asthma therapies and Churg-Strauss syndrome. J Allergy Clin Immunol 2002; 109:S1-S19
25. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52:2926-2935
26. Zwerina J, Axmann R, Manger B, et al. The emergence of antineutrophil cytoplasmic antibodies may precede the clinical onset of Churg-Strauss syndrome. Arthritis Rheum 2009; 60:626-627
27. Le Gall C, Pham S, Vignes S, et al. Inhaled corticosteroids and Churg-Strauss syndrome: a report of five cases. Eur Respir J 2000; 15:978-981
28. Wechsler ME, Finn D, Gunawardena D, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000; 117:708-713
29. Harrold LR, Patterson MK, Andrade SE, et al. Asthma drug use and the development of Churg-Strauss syndrome (CSS). Pharmacoepidemiol Drug Saf 2007; 16:620-626
30. Stanciu A, Ruppert A, Averous G, et al. Omalizumab and Churg-Strauss syndrome. Allergy 2008; 63:560-561
31. Food and Drug Administration. Final guidance: good pharmacovigilance practices and pharmacoepidemiologic assessment. Biotech Law Report 2005; 24:344-356
32. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, et al. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol 2007; 144:155-158
33. Pabst S, Tiyerili V, Grohé C. Apparent response to anti-IgE therapy in two patients with refractory "forme fruste" of Churg-Strauss syndrome. Thorax 2008; 63:747-748
34. Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170:583-593
35. Watts RA, Carruthers DM, Scott DG. Epidemiology of systemic vasculitis: changing incidence or definition? Semin Arthritis Rheum 1995; 25:28-34
36. Watts RA, Lane SE, Bentham G, et al. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000; 43:414-419
37. Watts RA, Gonzalez-Gay MA, Lane SE, et al. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis 2001; 60:170-172
38. Watts RA, Lane SE, Scott DG, et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis 2001; 60:1156-1157
39. Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, et al. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 2003; 49:388-393
40. Reinhold-Keller E, Zeidler A, Gutfleisch J, et al. Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology 2000; 39:1396-1402
41. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, et al. No difference in the incidences of vasculitides between north and south Germany: first results of the German vasculitis register. Rheumatology 2002; 41:540-549
42. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, et al. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 2005; 53:93-99
43. Haugeberg G, Bie R, Bendvold A, et al. Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol 1998; 17:364-368
44. Dadoniene J, Kirdaite G, Mackiewicz Z, et al. Incidence of primary systemic vasculitides in Vilnius: a university hospital population-based study. Ann Rheum Dis 2005; 64:335-336
45. Mohammad AJ, Jacobsson LT, Mahr AD, et al. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology 2007; 46: 1329-1337
46. Mahr A, Guillevin L, Poissonnet M, et al. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulmatosis, and Churg-Strauss syndrome in a French urban multi-ethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004; 51:92-99
47. Martin RM, Wilton LV, Mann RD. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription; event monitoring cohort studies. Pharmacoepidemiol Drug Saf 1999; 8:179-189
48. Loughlin JE, Cole JA, Rothman KJ, et al. Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients. Ann Allergy Asthma Immunol 2002; 88:319-325